Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies

Bora Jang, Hyokyoung Kwon, Pramila Katila, Seung Jin Lee, Hyukjin Lee

Research output: Contribution to journalReview articlepeer-review

77 Scopus citations

Abstract

Cancer causes > 8.2 million deaths annually worldwide; thus, various cancer treatments have been investigated over the past decades. Among them, combination drug therapy has become extremely popular, and treatment with more than one drug is often necessary to achieve appropriate anticancer efficacy. With the development of nanoformulations and nanoparticulate-based drug delivery, researchers have explored the feasibility of dual delivery of biological therapeutics to overcome the current drawbacks of cancer therapy. Compared with the conventional single drug therapy, dual delivery of therapeutics has provided various synergistic effects in addition to offering multimodality to cancer treatment. In this review, we highlight and summarize three aspects of dual-delivery systems for cancer therapy. These include (1) overcoming drug resistance by the dual delivery of chemical drugs with biological therapeutics for synergistic therapy, (2) targeted and controlled drug release by the dual delivery of drugs with stimuli-responsive nanomaterials, and (3) multimodal theranostics by the dual delivery of drugs and molecular imaging probes. Furthermore, recent developments, perspectives, and new challenges regarding dual-delivery systems for cancer therapy are discussed.

Original languageEnglish
Pages (from-to)113-133
Number of pages21
JournalAdvanced Drug Delivery Reviews
Volume98
DOIs
StatePublished - 1 Mar 2016

Keywords

  • Biological therapeutics
  • Cancer therapy
  • Dual delivery

Fingerprint

Dive into the research topics of 'Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies'. Together they form a unique fingerprint.

Cite this